Robert Califf

Robert Califf
Name	Robert Califf
Caption	25th Commissioner of Food and Drugs
Office	Commissioner of Food and Drugs
President	Joe Biden
Term start	February 17, 2022
Predecessor	Janet Woodcock (acting)
President2	Barack Obama
Term start2	February 25, 2016
Term end2	January 20, 2017
Predecessor2	Stephen Ostroff (acting)
Successor2	Scott Gottlieb
Office3	Deputy Commissioner for Medical Products and Tobacco
President3	Barack Obama
Term start3	January 2015
Term end3	February 2016
Predecessor3	Position established
Successor3	Position abolished
Birth date	21 January 1951
Birth place	Spartanburg, South Carolina, U.S.
Party	Democratic
Spouse	Lydia Isaac
Alma mater	Duke University (BS, MD)
Profession	Cardiologist, Medical researcher

Robert Califf. He is an American cardiologist and medical researcher who has served as the Commissioner of the Food and Drug Administration (FDA) under Presidents Barack Obama and Joe Biden. A prominent figure in clinical trial methodology and evidence-based medicine, his career has spanned leadership roles at Duke University, the Duke Clinical Research Institute, and the technology company Verily Life Sciences. His tenures at the FDA have focused on modernizing regulatory science, advancing medical device and pharmaceutical innovation, and addressing complex public health challenges.

Early life and education

Born in Spartanburg, South Carolina, he attended Duke University for his undergraduate studies, graduating with a degree in psychology. He remained at Duke University School of Medicine to earn his Doctor of Medicine degree. Following medical school, he completed his internship and residency in internal medicine at the University of California San Francisco (UCSF), and then returned to Duke University Medical Center for a fellowship in cardiology. His early academic work established a foundation in cardiovascular disease research.

Medical and academic career

He joined the faculty at Duke University School of Medicine, rising to become a professor of medicine and the founding director of the Duke Clinical Research Institute (DCRI), one of the world's largest academic clinical research organizations. His research significantly advanced the fields of cardiovascular outcomes research and the design of large-scale clinical trials. He held numerous leadership positions within the American Heart Association and served as an editor for major journals like the American Heart Journal. His work contributed to national guidelines from the American College of Cardiology.

First term as FDA Commissioner (2016–2017)

Nominated by President Barack Obama, he was confirmed by the United States Senate in a largely bipartisan vote. During this term, he emphasized the importance of the Precision Medicine Initiative and the Cancer Moonshot program. Key initiatives included efforts to streamline the regulation of digital health technologies and to enhance the FDA Sentinel System for post-market surveillance. His tenure also saw the implementation of the 21st Century Cures Act, which aimed to accelerate medical product development. He left the position upon the inauguration of President Donald Trump.

Return to academia and industry work

After his first term, he returned to Duke University as a professor and advisor. He also joined Alphabet Inc.'s healthcare subsidiary, Verily Life Sciences, and Google Health, where he worked on projects integrating technology and clinical evidence. During this period, he served on the boards of pharmaceutical companies like Portola Pharmaceuticals and remained active with the National Academy of Medicine. He continued to publish extensively on topics such as real-world evidence and regulatory science.

Second term as FDA Commissioner (2022–present)

Nominated by President Joe Biden, he was again confirmed by the United States Senate, becoming one of the few individuals to lead the Food and Drug Administration twice. His second term has been marked by navigating the agency's response to the ongoing COVID-19 pandemic, including the authorization of updated COVID-19 vaccine boosters and antiviral drugs. Other major challenges include addressing the opioid epidemic, regulating e-cigarettes and nicotine products, managing infant formula shortages, and overseeing the approval of novel therapies for conditions like Alzheimer's disease.

Policy positions and public health impact

A consistent advocate for strengthening the United States' clinical trial infrastructure, he has promoted the use of decentralized clinical trials and real-world data. He has emphasized the need for a robust Food and Drug Administration to ensure both the safety of the food supply and the efficacy of medical products. His leadership has focused on improving health equity in regulatory processes and preparing for future public health emergencies. His career reflects a deep commitment to applying rigorous scientific evidence to inform regulatory and public health decisions.

Category:1951 births Category:Living people Category:Commissioners of Food and Drugs Category:Duke University alumni Category:American cardiologists